A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Blisibimod (Primary)
  • Indications IgA nephropathy; Kidney disorders
  • Focus Proof of concept; Therapeutic Use
  • Acronyms BRIGHT-SC
  • Sponsors Anthera Pharmaceuticals
  • Most Recent Events

    • 09 Aug 2017 According to an Anthera Pharmaceuticals media release, the company has completed dosing on patients through 60 weeks in patients with IgAN in April.
    • 09 Aug 2017 According to an Anthera Pharmaceuticals media release, the company anticipates to report top-line data from the study later this month. Most patients, 42 of 57, completed at least 60 weeks of evaluation and 21 completed assessments through at least 104 weeks.
    • 15 Jun 2017 This trial has been completed in Spain (end date: 26 May 2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top